Narrative review reports the evolution of national adverse drug reaction monitoring in India, highlighting its growing integration into public health systems.
Pharmacovigilance is a branch of science that sprouted in the year 1960 after the incidence of thalidomide disaster. It is a master key for monitoring and evaluating Adverse Drug Reactions (ADRs) and plays an effective role in clinical practice, drug regulation systems, and public health programmes. India joined hands with the World Health Organisation (WHO) for international drug monitoring in the year 1998. Initially, the National Pharmacovigilance programme in India was not successful. Since 2010, the Pharmacovigilance programme of India (PvPI) has been successful with the Indian Pharmacopoeia Commission as the National Coordination center. The World Health Organization designated IPC-PvPI as a WHO Collaborating Centre for pharmacovigilance in public health programme and regulatory services from July 2017. In this review, we will discuss about life cycle, challenges, and perspectives of pharmacovigilance, milestones achieved by the pharmacovigilance programme in India, and its future consideration in the healthcare sector.
No takes yet. Share an insight, caveat, or question.
Rukmangathen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: